CarboDB Lipoarabinomannan 1010

From DrugPedia: A Wikipedia for Drug discovery

Revision as of 00:00, 15 January 2001 by Special:Contributions/ (Talk)
(diff) ←Older revision | Current revision (diff) | Newer revision→ (diff)
Jump to: navigation, search


Contents

Carbohydrate Name

Lipoarabinomannan

Carbohydrate Class

Miscellaneous

Source Microbe

Mycobacterium tuberculosis

Basic Structure

Mycobacterial lipoarabinomannan is a phosphatidylinositol anchored lipoglycan that consists of an α1-->6 linked backbone, substituted to varying degrees at position 2 with single α-Man residues, and directly attached to position 6 of the myo-inositol of a phosphatidylinositol (PI) anchor


Proposed functions

Reported to suppress T cell proliferation and to interfere with gamma interferon-mediated activation of macrophages. Other reported effects include inhibition of protein kinases, inhibition of the synthesis of mRNA encoding IL-2, IL-5, and granulocyte-macrophage colony stimulating factor (GM-CSF) in human T cells and activation of the complement cascade

Antigenic Nature used to produce antibodies

Heat killed Mycobacterium tuberculosis

Carrier Name

nil

Conjugation Method

nil

Antibodies

SMITB14

Antibody type and class

IgG1

Assay System

N\A

Cross-reactivity

SMITB14 bound to whole M. tuberculosis bacteria (H37Rv and Harlingen strains) as well as to the attenuated BCG, but not to other species such as Escherichia coli strains of various O serotypes, Streptococcus pneumoniae isolates, strains of Salmonella, Yersinia enterocolitica and Y. pseudotuberculosis and Nocardia sp.

Proposed epitopes

Arabinomannan portion of the antigen

Proposed Utility

This antibody might be involved in blocking of mycobacterial invasion. SMITB14 may prevent the uptake of M. tuberculosis through receptor(s) that facilitate bacterial survival and growth.

Weblink

PubMed Central

External Links